Header Ab 826


AB-836 is our capsid inhibitor

AB-836 is an oral capsid inhibitor that suppresses HBV DNA replication by interacting with HBV core protein, which is required for viral replication. AB-836 in combination with nucleos(t)ide analogues (NA) therapy is designed to further reduce viral replication in infected cells by preventing the assembly of functional viral capsids. In addition, AB-836 has potential to inhibit the replenishment of covalently closed circular DNA (cccDNA), the viral genetic reservoir which the virus needs to replicate itself.

Clinical data to-date

AB-836 is from a novel chemical series differentiated from competitor compounds and has the potential to provide increased efficacy and an enhanced resistance profile. AB-836 leverages a novel binding site within the core protein dimer-dimer interface, has shown to be active against NA resistant variants and has the potential to address certain known capsid resistant variants. Preliminary data from a Phase 1a/1b clinical trial has shown that AB-836 demonstrated robust antiviral activity, however, two patients in the highest dose cohort experienced alanine aminotransferase (ALT) elevations. Based on these observations along with potentially correlated immunological findings, we plan to conduct a Phase 1 clinical trial in healthy volunteers before progressing this program.

We believe AB-836 may have the following important advantages over other Class II capsid inhibitors:

  • Enhanced potency 
  • Enhanced resistant profile 
  • Once daily dosing 
  • Potential for co-formulation 

Learn more about AB-836 in practice.

View Publications